RxDoctor Payments Data

Christopher Carey, MD

Neurology · Ocean Springs, MSNPI 1932604022

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 846 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations.

$16,105in general payments, 2019–2025

Across 846 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$1K
  • AstraZeneca$1K
  • Acadia Pharmaceuticals Inc$1K
  • SK Life Science, Inc.$825
  • Eisai Inc.$783
  • plus $9K from 48 others

What the payments were for

  • Speaking & faculty fees$1301%
  • Food & beverage$15,93499%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)139$2,083
UCB, Inc.54$1,159
AstraZeneca(2 entities)46$1,142
Acadia Pharmaceuticals Inc54$1,024
SK Life Science, Inc.39$825
Eisai Inc.39$783
Pfizer53$743
Novartis37$705
Amgen(2 entities)28$667
EMD Serono, Inc.27$599
Lilly USA, LLC30$512
Biogen30$506
Neurocrine Biosciences, Inc.22$487
Teva Pharmaceuticals USA, Inc.20$457
Lundbeck LLC23$452
Genentech USA, Inc.20$440
Argenx US, Inc.19$377
Bristol Myers Squibb19$372
Merz Pharmaceuticals, LLC13$270
TG Therapeutics, Inc.15$236
Johnson & Johnson(2 entities)7$210
Acorda Therapeutics, Inc12$209
Jazz Pharmaceuticals Inc.9$179
ANI Pharmaceuticals, Inc.9$175
Otsuka America Pharmaceutical, Inc.9$157
Neurelis, Inc.8$142
Takeda Pharmaceuticals U.S.A., Inc.6$124
Sanofi4$122
Mallinckrodt Hospital Products Inc.4$72
Sumitomo Pharma America, Inc.9$67
Ipsen Biopharmaceuticals, Inc3$65
CSL Behring3$64
Microtransponder, Inc.1$59
Adamas Pharmaceuticals, Inc.3$56
Amylyx Pharmaceuticals, Inc.2$56
Amneal Pharmaceuticals LLC3$53
Tanabe Pharma America, Inc.3$47
Vanda Pharmaceuticals Inc.3$45
Biohaven Pharmaceutical Holding Company Ltd.2$44
Azurity Pharmaceuticals, Inc.3$39
Revance Therapeutics, Inc.2$37
Scilex Pharmaceuticals Inc.2$36
Banner Life Sciences, LLC1$21
Avion Pharmaceuticals1$20
Cycle Pharmaceuticals Inc1$20
Akcea Therapeutics, Inc.1$19
Boston Scientific1$18
MDD US Operations, LLC1$17
Almatica Pharma LLC1$17
Chiesi USA, Inc.1$16
Boehringer Ingelheim1$15
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$15
Supernus Pharmaceuticals, Inc.1$15
Kyowa Kirin, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,105 in reported general payments places this provider in the 75th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$81,393
Medicare patients
340
Services billed
699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate48$80,752
QuliptaAtogepant40$47,033
UbrelvyUbrogepant18$28,488
Levetiracetam119$2,752
Carbidopa-LevodopaCarbidopa/Levodopa145$2,592
Primidone51$2,055
Memantine Hcl99$1,696
Donepezil Hcl138$1,281
Rasagiline Mesylate13$1,229
Topiramate136$1,122
Entacapone12$1,116
Oxcarbazepine27$1,028
Zonisamide32$998
Amitriptyline Hcl91$994
Carbidopa-Levodopa ErCarbidopa/Levodopa19$875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$743$80,75248 claims
AbbVieQulipta, Ubrelvy$2,083$75,52158 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$53$84712 claims
Almatica Pharma LLCSertraline Hcl$17$14412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 111 neurology providers in Mississippi.

Other neurology in Ocean Springs

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →